Advertisement

Table of Contents

Highlights from the Literature

  • Highlights from the Literature
    What We're Reading
    Cancer Immunol Res June 1 2017 5 (6) 425-425;

Cancer Immunology at the Crossroads

Meeting Report

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    4-1BB–Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells
    Michiko Harao, Marie-Andrée Forget, Jason Roszik, Hui Gao, Gildy V. Babiera, Savitri Krishnamurthy, Jessica A. Chacon, Shumin Li, Elizabeth A. Mittendorf, Sarah M. DeSnyder, Korrene F. Rockwood, Chantale Bernatchez, Naoto T. Ueno, Laszlo G. Radvanyi, Luis Vence, Cara Haymaker and James M. Reuben
    Cancer Immunol Res June 1 2017 5 (6) 439-445; DOI:10.1158/2326-6066.CIR-16-0364

    Triple-negative breast cancers have low somatic mutational loads. By culturing tumor-infiltrating lymphocytes with agonistic 4-1BB mAb, tumor-specific T cells were expanded and the mutations to which they responded identified, providing a rationale for adoptive T cell therapy.

Research Articles

  • Research Articles
    Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
    Xinqi Wu, Jingjing Li, Erin M. Connolly, Xiaoyun Liao, Jing Ouyang, Anita Giobbie-Hurder, Donald Lawrence, David McDermott, George Murphy, Jun Zhou, Matthias Piesche, Glenn Dranoff, Scott Rodig, Margaret Shipp and F. Stephen Hodi
    Cancer Immunol Res June 1 2017 5 (6) 446-454; DOI:10.1158/2326-6066.CIR-16-0385

    Galectin-1 is often produced by tumors and is protumoral, proangiogenic, and immunosuppressive. Ipilimumab plus bevacizumab induced production of neutralizing antibodies to galectin-1, which correlated with better clinical outcomes in metastatic melanoma patients, highlighting its utility as a therapeutic target.

  • Research Articles
    RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation
    Christina Engel, Grethe Brügmann, Silke Lambing, Larissa H. Mühlenbeck, Samira Marx, Christian Hagen, Dorottya Horváth, Marion Goldeck, Janos Ludwig, Anna-Maria Herzner, Jan W. Drijfhout, Daniela Wenzel, Christoph Coch, Thomas Tüting, Martin Schlee, Veit Hornung, Gunther Hartmann and Jasper G. Van den Boorn
    Cancer Immunol Res June 1 2017 5 (6) 455-467; DOI:10.1158/2326-6066.CIR-16-0129-T

    Solid tumors are generally hypoxic. RIG-I, but not IFNα, still functioned under hypoxia. Activating RIG-I and using vitamin C to scavenge free radicals in a melanoma model augmented NK and CD8+ T cell antitumor functions and prolonged survival.

  • Research Articles
    A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
    Jeremy B. Foote, Marleen Kok, James M. Leatherman, Todd D. Armstrong, Bridget C. Marcinkowski, Laureen S. Ojalvo, David B. Kanne, Elizabeth M. Jaffee, Thomas W. Dubensky Jr and Leisha A. Emens
    Cancer Immunol Res June 1 2017 5 (6) 468-479; DOI:10.1158/2326-6066.CIR-16-0284

    The efficacy and immune dynamics of STING modulation in the toleragenic tumor microenvironment were examined. Combining a STING agonist, PD-L1 blockade, and OX40R stimulation created an inflamed tumor microenvironment that recruited T cells and activated tumor-specific immunity.

  • Research Articles | AuthorChoice
    Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
    Jun Zhou, Kathleen M. Mahoney, Anita Giobbie-Hurder, Fengmin Zhao, Sandra Lee, Xiaoyun Liao, Scott Rodig, Jingjing Li, Xinqi Wu, Lisa H. Butterfield, Matthias Piesche, Michael P. Manos, Lauren M. Eastman, Glenn Dranoff, Gordon J. Freeman and F. Stephen Hodi
    Cancer Immunol Res June 1 2017 5 (6) 480-492; DOI:10.1158/2326-6066.CIR-16-0329

    Melanoma cells could secrete several splice variants of PD-L1. Secretion differed among patients, and was affected by checkpoint therapy, with some changes associated with progressive disease, and others with favorable outcomes, suggesting circulating PD-L1 as a dynamic biomarker.

  • Research Articles
    Tumor-Derived α-Fetoprotein Directly Drives Human Natural Killer–Cell Activation and Subsequent Cell Death
    Lazar Vujanovic, Elizabeth C. Stahl, Angela D. Pardee, David A. Geller, Allan Tsung, Simon C. Watkins, Gregory A. Gibson, Walter J. Storkus and Lisa H. Butterfield
    Cancer Immunol Res June 1 2017 5 (6) 493-502; DOI:10.1158/2326-6066.CIR-16-0216

    Low NK cell numbers, function, and infiltration into tumors predict poor outcomes for patients with hepatocellular carcinoma (HCC). Tumor-derived α-fetoprotein (AFP) from HCCs directly impacted NK cell function and viability, through both the AFP protein and AFP's low-molecular-mass cargo.

  • Research Articles
    Combining DNA Vaccine and AIDA-1 in Attenuated Salmonella Activates Tumor-Specific CD4+ and CD8+ T-cell Responses
    Yu Mei, Lixiang Zhao, Yonghao Liu, Huanle Gong, Yuan Song, Lei Lei, Ying Zhu, Ziqi Jin, Shoubao Ma, Bo Hu, Qing Sun and Haiyan Liu
    Cancer Immunol Res June 1 2017 5 (6) 503-514; DOI:10.1158/2326-6066.CIR-16-0240-T

    Effective tumor vaccines activate both CD4+ and CD8+ T cells. A melanoma DNA vaccine delivered by a bacterial system that ensured presentation of both class I and class II peptides activated both arms of the adaptive immune response.

Back to top

Jump to

Advertisement